Testosterone vs GH peptides for muscle and recomposition: what each one actually changes

TL;DR

• Testosterone is the muscle lever - in controlled trials it reliably increases fat-free mass and muscle size, and strength rises most when it is combined with resistance training.
• The GH to IGF-1 axis is mostly a composition and connective-tissue lever - growth hormone trials show less fat (especially visceral fat with tesamorelin), more lean mass that may partly be water, and more collagen synthesis in tendon and muscle, but not reliably more strength.
• GH-axis peptides have not been tested for muscle outcomes - CJC-1295 and ipamorelin are investigational; their effect on strength or muscle size in healthy adults is unestablished because those trials have not been funded or run.
• The pairing logic is complementary mechanisms - in older-adult trials, growth hormone plus testosterone moved lean mass, fat and aerobic capacity more consistently than either alone, at the cost of more side effects.
• Each brings its own monitoring - fertility and haematocrit on the testosterone side; glucose, fluid and IGF-1 on the GH side.
• The sensible starting point is a baseline panel and a physician, who can tell you which axis, if either, is worth acting on.

Educational content, not medical advice. No doses, cycles or protocols appear.

---

Why this comparison keeps coming up

Ask anyone who trains seriously what they want from a hormone-axis intervention and the answer is more muscle, less fat around the middle, faster recovery, and joints that tolerate the training. Testosterone and growth hormone peptides are marketed into exactly that wish list.

The companion piece on GH peptides versus TRT (currently in review) treats them as two separate endocrine axes and two separate clinical decisions. This article asks the practical follow-on question: when each one does work, what does it actually change in the body, and why do people pair them? The honest answer is that they do different jobs, and the evidence for each job is uneven.

What each one actually does to muscle

Evidence tier: established human physiology and mechanistic studies.

Testosterone. Testosterone binds the androgen receptor in skeletal muscle and increases muscle protein synthesis. It also promotes recruitment of satellite cells, the muscle stem cells that donate nuclei to growing fibres, which supports sustained hypertrophy. The net effect is more contractile tissue: bigger fibres that can produce more force. Its effects are dose-dependent and training-dependent.

The GH to IGF-1 axis. Growth hormone is released in pulses from the pituitary under the control of GHRH, and much of its effect runs through IGF-1, produced largely in the liver and also locally in muscle and tendon (see the GH and IGF-1 axis explained). Growth hormone itself is strongly lipolytic: it mobilises stored fat, and visceral fat appears particularly responsive. It also causes sodium and water retention. And in connective tissue, it drives collagen synthesis. What it does not appear to do, in healthy adults, is substantially raise contractile protein synthesis. That distinction explains most of the outcome differences below.

GH peptides such as sermorelin, CJC-1295 and tesamorelin do not supply growth hormone; they prompt the pituitary to release more of its own. Their effects should therefore be expected to resemble, and be no larger than, those of the growth hormone they release. How that differs from injecting recombinant GH is covered in HGH versus GH peptides.

Outcomes compared

Evidence tier: randomised controlled trials and systematic reviews, mostly with testosterone or recombinant growth hormone rather than GH peptides.

Lean mass and strength. The clearest muscle data for testosterone come from a 1996 NEJM trial by Bhasin and colleagues, which gave healthy young men testosterone at doses well above the normal physiological range. Fat-free mass, muscle cross-sectional area and strength all increased, and the gains were largest when testosterone was combined with structured resistance training. That is a research finding about supraphysiological exposure. Using testosterone above the normal range is outside medical practice, carries real risks, and is not something Vivre Labs offers. In men with diagnosed hypogonadism, physiological replacement is a different and far more modest proposition: a 2016 meta-analysis of randomised trials found testosterone supplementation increased lean mass and reduced fat mass, while the Testosterone Trials in older men found moderate improvements in sexual function and only small improvements in walking distance.

Growth hormone tells a different story. A 2007 systematic review in healthy older adults (Liu, Annals of Internal Medicine) found that growth hormone increased lean mass and reduced fat mass by similar amounts, but was associated with more oedema, joint pain, carpal tunnel syndrome and gynaecomastia, and the authors concluded it could not be recommended as an anti-ageing therapy. A 2008 review in athletes by the same group found lean body mass increased but strength and exercise capacity did not improve. Part of the lean-mass gain measured on body-composition scans is likely extracellular water rather than new muscle, because fluid retention is a known effect of growth hormone.

Fat and visceral fat. This is where the GH axis is strongest. Tesamorelin, a GHRH analogue, reduced visceral adipose tissue by about 15 percent over 26 weeks in a randomised trial in people with HIV-associated abdominal fat, against a small increase on placebo (Falutz, NEJM 2007), and it is FDA-approved for that narrow indication. Testosterone in hypogonadal men also reduces fat mass, but with less specificity for the visceral compartment. For the wider picture on this target, see how to reduce visceral fat.

Connective tissue. In a study of healthy young men, two weeks of growth hormone increased collagen synthesis in both tendon and skeletal muscle connective tissue, while myofibrillar (contractile) protein synthesis was unchanged (Doessing, Journal of Physiology 2010). That is the mechanistic root of the "joint sparing" idea discussed below.

Why people pair them: the complementary logic

Evidence tier: mechanism plus a small number of randomised trials in older adults.

The rationale for combining the two is not that more hormones equal more muscle. It is that the two axes do different jobs, and the gaps in one overlap with the strengths of the other.

Testosterone is the lever for contractile muscle: it is what moves fibre size and force. The GH to IGF-1 axis contributes little there, but it is the stronger lever for fat mobilisation (particularly visceral fat), and it supports collagen synthesis in the tendons and connective tissue that have to carry the load a bigger, stronger muscle produces. On paper, one builds the engine and the other works on the chassis and the fuel tank.

There is also a physiological interaction. Androgens increase growth hormone secretion and IGF-1 production, and in hypopituitary men receiving both, the two have been reported to have independent and additive effects on protein metabolism. The interaction in the other direction is weak: GH peptides do not meaningfully raise testosterone in a normally functioning axis.

The clinical context in which this pairing is most often discussed is narrow and specific. A typical example is a man with diagnosed hypogonadism who is already on physician-managed testosterone replacement, whose muscle and energy have responded but whose visceral fat or recovery between training sessions has not. His physician might consider whether a GH-axis peptide is worth adding for that specific target, after checking IGF-1, glucose markers and the rest of a baseline panel, and with a plan for what will be monitored and what would prompt stopping. That is a different situation from a healthy person assembling a stack from internet forums, and the evidence below should be read with that difference in mind.

What the combination evidence shows, and what it does not

Evidence tier: two randomised controlled trials of recombinant GH plus testosterone in older adults. No trials of GH peptides plus testosterone.

Two trials do most of the work here.

Blackman and colleagues (JAMA, 2002) randomised 131 healthy adults aged 65 to 88 to growth hormone, sex steroids, both, or placebo for 26 weeks. In men, lean body mass rose most with growth hormone plus testosterone, fat mass fell in the growth hormone groups, and aerobic capacity improved with the combination. Strength gains were marginal. Side effects were frequent: oedema, carpal tunnel symptoms, joint pain, and diabetes or glucose intolerance in substantially more of the growth hormone treated men than controls. The authors recommended that growth hormone in older people be confined to controlled studies.

Giannoulis and colleagues (JCEM, 2006) randomised 80 healthy men aged 65 to 80 to growth hormone, testosterone, both, or placebo for six months, using lower growth hormone exposure. Lean body mass rose with growth hormone alone and with the combination; total fat mass fell and aerobic capacity and thigh muscle area increased only with the combination. Strength improved on one of six measures. No major adverse effects were reported, and the authors concluded that beneficial changes were seen more often with the combination than with either hormone alone.

What these trials do not show:

• They used recombinant growth hormone, not GH peptides. Whether a GHRH analogue or a secretagogue added to testosterone reproduces these effects has not been studied.
• They studied older adults, not trained people in their thirties or forties seeking recomposition.
• Strength gains were small or marginal, even when lean mass rose.
• The side-effect burden grew with the combination, particularly fluid retention and glucose handling.

So the complementary logic has human support in older adults using approved hormones under trial monitoring; whether it holds for GH peptides in younger people is unestablished, because no one has funded that trial.

Joint and connective tissue: what "joint sparing" can and cannot mean

Evidence tier: short-term mechanistic human study; no clinical outcome trials.

"Joint sparing" is one of the most common reasons people say they want a GH-axis peptide alongside training. The mechanistic basis is real: growth hormone increases collagen synthesis in tendon and in the connective tissue within muscle, and local IGF-1 rises alongside it.

What that does not establish is a clinical outcome. No trial has shown that GH-axis peptides reduce tendon injury, improve tendon strength, or relieve joint pain in people who train. Higher collagen synthesis over two weeks is not the same as a stronger tendon over months. And in the growth hormone trials in older adults, joint pain and carpal tunnel symptoms were among the more common side effects, likely reflecting fluid retention in soft tissue.

Recovery from an existing tendon or joint problem is a separate question with separate candidates. Peptides such as BPC-157 and TB-500, available together in the GLOW protocol, are discussed for that purpose, but their evidence is overwhelmingly from animal studies, both are investigational, and neither is a GH-axis compound.

Risks and monitoring: each one, and together

Evidence tier: regulatory labelling, large outcome trials and systematic reviews.

Testosterone.

• Fertility. Exogenous testosterone suppresses LH and FSH and therefore sperm production; this is an expected effect, not a rare one. Recovery after stopping is usually possible but can take many months and is not guaranteed. See does TRT cause infertility and enclomiphene, hCG and kisspeptin.
• Haematocrit. Testosterone raises red cell mass, which is monitored and can require action.
• Cardiovascular. The TRAVERSE trial (NEJM, 2023) found testosterone replacement non-inferior to placebo for major cardiovascular events in men with hypogonadism, with higher rates of atrial fibrillation, acute kidney injury and pulmonary embolism. Those results apply to physician-managed replacement in diagnosed men, not to above-range use.
• Prostate and blood pressure are monitored as appropriate for age.

The GH to IGF-1 axis.

• Glucose and insulin resistance. Growth hormone opposes insulin action; glucose intolerance and new diabetes were more common in the growth hormone arms of the older-adult trials.
• Fluid. Oedema, joint pain and carpal tunnel symptoms are the most consistent adverse effects of growth hormone in healthy adults.
• IGF-1 and cancer risk. Observational studies link higher circulating IGF-1 with higher risk of some common cancers. Whether raising IGF-1 with a peptide increases cancer risk has not been shown, but it is a live debate, and it is one reason IGF-1 is monitored rather than pushed as high as possible.
• Regulatory status. Tesamorelin is FDA-approved only for excess abdominal fat in adults with HIV-associated lipodystrophy. Sermorelin's approved product was discontinued in 2008, not for safety reasons. CJC-1295 and ipamorelin are investigational and not FDA-approved; the CJC-1295 human data are hormone-level studies, showing prolonged rises in GH and IGF-1 in healthy adults (Teichman, JCEM 2006), with no muscle-outcome trials.

Together. Combining the two stacks the monitoring burden: testosterone, haematocrit, blood pressure and fertility considerations on one side; IGF-1, fasting glucose or HbA1c, and fluid symptoms on the other. In the Blackman trial, side effects were common enough that the combination is not something to assemble without a clinician watching both axes. Start with the baseline biomarker panel so there is something to compare against.

Where Vivre Labs fits

Vivre Labs does not supply testosterone and does not support its use outside a diagnosis. If low testosterone is the question, start with the TRT guide and a physician who will test properly.

On the GH axis, these are options to discuss with a physician, with baseline bloodwork first:

• Tesamorelin is a GHRH analogue with randomised trial evidence for visceral fat reduction; it is FDA-approved only for HIV-associated abdominal fat, and other uses are off-label. More in tesamorelin as a GHRH analogue.
• The metabolic protocol pairs tirzepatide with tesamorelin for people whose recomposition goal is driven by weight and blood sugar; it is relevant to losing fat without losing muscle.
• CJC-1295 and ipamorelin are investigational and not FDA-approved; human data show increases in GH and IGF-1, not muscle or strength outcomes. They are offered together as the lean mass and sleep quality protocol. Background in CJC-1295 and ipamorelin explained.
• Sermorelin is a GHRH analogue whose approved product was discontinued for commercial, not safety, reasons.

If your main goal is muscle, the build muscle goal page sets out where training, nutrition and these options each sit.

Frequently asked questions

Is testosterone or a GH peptide better for building muscle? For contractile muscle and strength, testosterone has far stronger evidence. Growth hormone increases measured lean mass, partly through water, without reliably improving strength, and GH peptides have not been tested for muscle outcomes in healthy adults.

Do GH peptides help with body recomposition? The strongest GH-axis signal is fat loss, particularly visceral fat: tesamorelin has randomised trial evidence for reducing it in HIV-associated abdominal fat. For other peptides and other populations, a recomposition benefit is plausible from mechanism but unestablished, because the trials have not been run.

Why do people take TRT and GH peptides together? Because the two axes do different things: testosterone drives muscle protein synthesis, while the GH to IGF-1 axis targets fat, fluid and connective tissue. Trials of recombinant GH plus testosterone in older adults found more consistent gains in lean mass, fat loss and aerobic capacity than either alone, with more side effects. No trial has tested GH peptides combined with testosterone.

Can growth hormone peptides protect my joints? Growth hormone increases collagen synthesis in tendon and muscle connective tissue in short-term human studies. Whether that translates into fewer injuries or less joint pain has not been tested, and joint pain is itself a recognised side effect of growth hormone.

Related reading

• The GH and IGF-1 axis explained
• HGH versus GH peptides
• Sermorelin vs CJC-1295 vs tesamorelin
• Testosterone replacement therapy: the guide
• How to lose fat without losing muscle
• TRT and GH peptides - why they work better as a pair than as substitutes

Part of The Complete Guide to Growth Hormone Peptides

Talk it through with a physician first. Start with a baseline biomarker panel, then discuss whether either axis is worth acting on.

---

This article is educational and does not constitute medical advice. No doses, cycles, schedules, combination instructions or administration guidance appear in it, and none should be inferred. Testosterone use above the normal physiological range is outside medical practice and is not supported by Vivre Labs. Tesamorelin is FDA-approved only for excess abdominal fat in adults with HIV-associated lipodystrophy; CJC-1295 and ipamorelin are investigational and not FDA-approved. Combination evidence comes from recombinant growth hormone with testosterone in older adults and should not be extrapolated to GH peptides or younger people. Any use is a matter for a treating physician. Claims for the Malaysian market are subject to MAB requirements.

References

• Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. New England Journal of Medicine 1996;335(1):1-7.
• Corona G, et al. Therapy of endocrine disease: testosterone supplementation and body composition: results from a meta-analysis study. European Journal of Endocrinology 2016.
• Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. New England Journal of Medicine 2016;374(7).
• Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy (TRAVERSE). New England Journal of Medicine 2023;389(2):107-117.
• Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Annals of Internal Medicine 2007;146(2).
• Liu H, Bravata DM, Olkin I, et al. Systematic review: the effects of growth hormone on athletic performance. Annals of Internal Medicine 2008;148(10).
• Doessing S, Heinemeier KM, Holm L, et al. Growth hormone stimulates the collagen synthesis in human tendon and skeletal muscle without affecting myofibrillar protein synthesis. Journal of Physiology 2010;588(2).
• Blackman MR, Sorkin JD, Munzer T, et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 2002;288(18).
• Giannoulis MG, Sonksen PH, Umpleby M, et al. The effects of growth hormone and/or testosterone in healthy elderly men: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism 2006;91(2):477-484.
• Gibney J, Wolthers T, Johannsson G, et al. Growth hormone and testosterone interact positively to enhance protein and energy metabolism in hypopituitary men. American Journal of Physiology - Endocrinology and Metabolism 2005.
• Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine 2007;357(23).
• Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism 2006;91(3).
• Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363(9418):1346-1353.
• World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertility and Sterility 1996.
• US Food and Drug Administration. EGRIFTA (tesamorelin) prescribing information.